Timothy Schmidt

Jun 3, 2024 | nature.com | Timothy Schmidt

In the manuscript that accompanies this editorial, Derman, et al. report the final analysis of a phase 2 clinical trial of extended daratumumab, carfilzomib, lenalidomide, and dexamethasone (DaraKRd) without transplant for patients with newly diagnosed multiple myeloma (MM) [1]. Patients were treated with the quadruplet regimen for two years, followed by lenalidomide maintenance per standard of care.

Apr 21, 2024 | nature.com | Natalie S. Callander |Jonathan Kaufman |Jacob P. Laubach |Timothy Schmidt |Brandi N. Reeves |Binod Dhakal | +8 more

AbstractIn the MASTER study (NCT03224507), daratumumab+carfilzomib/lenalidomide/dexamethasone (D-KRd) demonstrated promising efficacy in transplant-eligible newly diagnosed multiple myeloma (NDMM). In GRIFFIN (NCT02874742), daratumumab+lenalidomide/bortezomib/dexamethasone (D-RVd) improved outcomes for transplant-eligible NDMM. Here, we present a post hoc analysis of patients with high-risk cytogenetic abnormalities (HRCAs; del[17p], t[4;14], t[14;16], t[14;20], or gain/amp[1q21]).

Jan 24, 2024 | nature.com | Timothy Schmidt |Rafael Fonseca |Rajshekhar Chakraborty |Meera Mohan |Luciano Costa |Douglas Sborov | +1 more

AbstractExtra copies of chromosome 1q21 (+1q: gain = 3 copies, amp >= 4 copies) are associated with worse outcomes in multiple myeloma (MM). This systematic review assesses the current reporting trends of +1q, the efficacy of existing regimens on +1q, and its prognostic implications in MM randomized controlled trials (RCTs). Pubmed, Embase and Cochrane Registry of RCTs were searched from January 2012 to December 2022. Only MM RCTs were included.

Jan 24, 2024 | nature.com | Rohan J. Hudson |Timothy Schmidt

AbstractExciton science sits at the intersection of chemical, optical and spin-based implementations of information processing, but using excitons to conduct logical operations remains relatively unexplored. Excitons encoding information could be read optically (photoexcitation–photoemission) or electrically (charge recombination–separation), travel through materials via exciton energy transfer, and interact with one another in stimuli-responsive molecular excitonic devices.

Aug 14, 2023 | cancernetwork.com | Joselle M. Cook |Matthew James Pianko |Luciano Costa |Timothy Schmidt

As part of a CancerNetwork® Frontline Forum program, Joselle Cook, MBBS; Matthew James Pianko, MD; Luciano Costa, MD, PhD; and Timothy Schmidt, MD, reviewed key data updates and real-world practice findings in newly diagnosed multiple myeloma (NDMM), and how they may impact patient subgroups including those with transplant-ineligible NDMM.